Journal of Clinical and Aesthetic Dermatology

Psoriasis and Cutaneous Supplement 2016

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/729153

Contents of this Issue

Navigation

Page 31 of 35

escalation study to evaluate the efficacy and safety of A SP015K, a novel Janus kinase (JAK) inhibitor, in patients with moderate to severe psoriasis. Br J Dermatol. 2015;173(3):767–776. 97. Golden JB, Wang Y, Fritz Y, et al. Chronic, not acute, skin- specific inflammation promotes thrombosis in psoriasis murine models. J Transl Med. 2015;13:382. 98. Naik HB, Natarajan B, Stansky E, et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET/CT and neutrophil activation in a prospective observational study. Arterioscler Thromb Vasc Biol. 2015;35(12):2667–2676. 99. Shalom G, Zisman D, Bitterman H, et al. Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person- year study. JAMA Dermatol. 2015;151(5):533–538. 100. Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol. 2015;151(9):961–969. 101. Nikamo P, Lysell J, Stahle M. Association with genetic variants in the IL-23 and NF-kappaB pathways discriminates between mild and severe psoriasis skin disease. J Invest Dermatol. 2015;135(8):1969–1976. 102. Wohn C, Brand A, van Ettinger K, et al. Gradual development of psoriatic skin lesions by constitutive low- level expression of IL-17A. Cell Immunol. 2015 Nov 26 . 103. Hartwig T, Pantelyushin S, Croxford AL, Kulig P, Becher B. Dermal IL-17-producing gammadelta T cells establish long-lived memory in the skin. Eur J Immunol. 2015;45(11): 3022–3033. 104. Banerjee D, Zhao L, Wu L, et al. Small molecule mediated inhibition of RORgamma-dependent gene expression and autoimmune disease pathology in vivo. Immunology. 2016;147(4):399–413. 105. Schukur L, Geering B, Charpin-El Hamri G, Fussenegger M. Implantable synthetic cytokine converter cells with AND-gate logic treat experimental psoriasis. Science Translational Medicine. 2015;7(318):318ra201. 106. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3): 499–510. 107. Blauvelt A, Armstrong AW, Krueger GG. Essential truths for the care and management of moderate-to-severe psoriasis. J Drugs Dermatol. 2015;14(8):805–812. 108. Blauvelt A, Lebwohl MG, Bissonnette R. IL-23/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies. J Invest Dermatol. 2015;135(8): 1946–1953. 109. Blauvelt A. Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to-severe plaque psoriasis. Expert Opin Biol Ther. 2016;16(2):255–263. 110. Belasco J, Louie JS, Gulati N, et al. Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis & Rheumatology (Hoboken, NJ). 2015;67(4): 934–944. 111. Karreman M, Weel A, van der Ven M, et al. Screening for P SA in primary care psoriasis patients with muscoloskeletal complaints with PEST, PASE, and EARP. Rome: EULAR 2015;2015. 112. Helliwell PS. Psoriasis Epidemiology Screening Tool (PEST): a report from the GRAPPA 2009 annual meeting. J Rheumatol. 2011;38(3):551–552. 113. Ibrahim GH, Buch MH, Lawson C, et al. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009;27(3):469–474. 114. Coates LC, Helliwell PS. Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol. 2016;43(2):356–361. 115. Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016;137(1):19–27. 116. Boyd T, Kavanaugh A. Novel approaches to biological therapy for psoriatic arthritis. Expert Opin Biol Ther. 2016;16(2): 173–186. 117. Ungprasert P, Thongprayoon C, Davis JM, 3rd. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to nonsteroidal anti-inflammatory drugs: a meta-analysis. Semin Arthritis Rheum. 2016;45(4):428–438. 118. Kavanaugh A, van der Heijde D, Beutler A, et al. Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab tTherapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care Res (Hoboken). 2016;68(2):267–274. 119. Vogelzang EH, Kneepkens EL, Nurmohamed MT, et al. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis. 2014;73(12): 2178–2182. 120. Kavanaugh A, Smolen JS. The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials. Clin Exp Rheumatol. 2013;31(4 Suppl 78):S19–S21. 121. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. New Engl J Med. 2015;373(14):1329–1339. 122. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–1146. 123. Mease PJ, van der Heijde D, Ritchlin CT, et al. A randomized, double-blind, active- and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients naïve to biologic disease modifying anti-rheumatic drugs with active psoriatic arthritis [abstract]. Arthritis Rheumatol. 2015;67 (Suppl 10). http://acrabstracts.org/abstract/a- S 2 8 S U P P L E M E N T T O T H E J O U R N A L O F C L I N I C A L A N D A E S T H E T I C D E R M AT O L O G Y [ S E P T E M B E R 2 0 1 6 • V O L U M E 9 • N U M B E R 9 ]

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - Psoriasis and Cutaneous Supplement 2016